임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

60건 표시 (상위 60건)

3상모집 예정· Diabetic Retinopathy
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
리드: 머크(MSD)
상세 →NCT07705607
3상모집 예정· Diabetic Retinopathy
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
리드: 머크(MSD)
상세 →NCT07705555
3상모집 중· Non-small Cell Lung Cancer
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
리드: 머크(MSD)
상세 →NCT07554339
3상모집 중· Non-small Cell Lung Cancer
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
리드: 머크(MSD) · 협력: 모더나
상세 →NCT07513376
3상모집 중· Bladder Cancer
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
리드: 머크(MSD)
상세 →NCT07419295
3상모집 중· Carcinoma, Renal Cell
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
리드: 머크(MSD)
상세 →NCT07489495
3상모집 중· Von Hippel-Lindau Disease
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
리드: 머크(MSD)
상세 →NCT07405164
3상모집 중· Non-small Cell Lung Cancer
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
리드: 머크(MSD)
상세 →NCT07431827
3상모집 중· Ovarian Neoplasms
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
리드: 머크(MSD)
상세 →NCT07318558
3상모집 중· Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
리드: 머크(MSD)
상세 →NCT07216703
3상모집 중· Renal Cell Carcinoma
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
리드: 머크(MSD)
상세 →NCT07227402
3상모집 중단 (진행 중)· Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
리드: 머크(MSD)
상세 →NCT07216482
3상모집 중· Human Immunodeficiency Virus (HIV)
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
리드: 머크(MSD)
상세 →NCT07071623
3상모집 중· Non-small Cell Lung Cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
협력: 머크(MSD)
상세 →NCT06899126
3상모집 중· Insomnia
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
리드: 머크(MSD)
상세 →NCT06655883
3상모집 중· Non-small Cell Lung Cancer
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
리드: 머크(MSD)
상세 →NCT07190248
3상모집 중· Human Immunodeficiency Virus (HIV)
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
리드: 머크(MSD)
상세 →NCT07044297
3상모집 중· Breast Neoplasms
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
리드: 머크(MSD)
상세 →NCT07060807
3상모집 중· Colon Adenocarcinoma
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
리드: 머크(MSD)
상세 →NCT06997497
3상모집 중· Breast Neoplasms
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
리드: 머크(MSD)
상세 →NCT06966700
3상모집 중· Healthy
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
리드: 머크(MSD)
상세 →NCT07013487
3상모집 중· Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
협력: 머크(MSD)
상세 →NCT05815927
3상모집 중· Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
리드: 머크(MSD)
상세 →NCT06952504
3상모집 중· Prostate Cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
리드: 머크(MSD)
상세 →NCT06925737
3상모집 중· Ovarian Cancer
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
리드: 머크(MSD)
상세 →NCT06824467
3상모집 중· Esophageal Squamous Cell Carcinoma
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
협력: 머크(MSD)
상세 →NCT06644781
3상모집 중단 (진행 중)· Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
협력: 머크(MSD)
상세 →NCT06726265
3상모집 중· Triple Negative Breast Neoplasms
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
리드: 머크(MSD)
상세 →NCT06841354
3상모집 중· Gastric Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
협력: 머크(MSD)
상세 →NCT06731478
3상모집 중· Glioblastoma
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
협력: 머크(MSD)
상세 →NCT06556563
3상모집 중· Diffuse Large B-Cell Lymphoma
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
리드: 머크(MSD)
상세 →NCT06717347
3상모집 중· Coronavirus Disease (COVID-19)
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
리드: 머크(MSD)
상세 →NCT06667700
3상모집 중· Crohn Disease
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
리드: 머크(MSD)
상세 →NCT06651281
3상모집 중단 (진행 중)· Lung Cancer
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
리드: 머크(MSD)
상세 →NCT06698042
3상모집 중· Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
리드: 머크(MSD) · 협력: 모더나
상세 →NCT06623422
3상모집 중· Triple Negative Breast Cancer
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
협력: 길리어드, 머크(MSD)
상세 →NCT06081244
3상모집 중단 (진행 중)· HIV-1-infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
상세 →NCT06630286
3상모집 중단 (진행 중)· HIV-1-Infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
상세 →NCT06630299
3상모집 중· Cytomegalovirus Infections
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
협력: 머크(MSD)
상세 →NCT06407232
3상모집 중단 (진행 중)· Hypercholesterolemia
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
리드: 머크(MSD)
상세 →NCT06492291
3상모집 중단 (진행 중)· Cervical Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
리드: 머크(MSD)
상세 →NCT06459180
3상모집 중단 (진행 중)· Essential Thrombocythemia
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
리드: 머크(MSD)
상세 →NCT06456346
3상모집 중· Triple-Negative Breast Cancer
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
리드: 머크(MSD)
상세 →NCT06393374
3상모집 중단 (진행 중)· Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
리드: 머크(MSD)
상세 →NCT06305754
3상모집 중· Non-small Cell Lung Cancer
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
리드: 머크(MSD)
상세 →NCT06422143
3상모집 중· Crohn's Disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
리드: 머크(MSD)
상세 →NCT06430801
3상모집 중· Neuromuscular Blocks
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
협력: 머크(MSD)
상세 →NCT06136585
3상모집 중· Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
리드: 머크(MSD)
상세 →NCT06345729
3상모집 중· Thrombocythemia, Essential
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
리드: 머크(MSD)
상세 →NCT06351631
3상모집 중· Small Cell Lung Cancer
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
협력: 머크(MSD)
상세 →NCT06203210
3상모집 중단 (진행 중)· Gastroesophageal Cancer
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
리드: 머크(MSD)
상세 →NCT06356311
3상모집 중· Breast Neoplasms
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
리드: 머크(MSD)
상세 →NCT06312176
3상모집 중· Non Small Cell Lung Cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
리드: 머크(MSD)
상세 →NCT06312137
3상모집 중· Prostate Cancer Metastatic
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
리드: 머크(MSD)
상세 →NCT06136624
3상모집 중단 (진행 중)· Essential Thrombocythemia
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
리드: 머크(MSD)
상세 →NCT06079879
3상모집 중· Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
리드: 머크(MSD)
상세 →NCT06136650
3상모집 중· Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
리드: 머크(MSD)
상세 →NCT06170788
3상모집 중· Chronic Lymphocytic Leukemia
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
리드: 머크(MSD)
상세 →NCT06136559
3상모집 중단 (진행 중)· Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
리드: 머크(MSD)
상세 →NCT06132958
3상모집 중· Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
리드: 머크(MSD) · 협력: 모더나
상세 →NCT06077760

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.